News

Move to sell statins over the counter raises concerns

BMJ 2004; 328 doi: 10.1136/bmj.328.7450.1221-b (Published 20 May 2004)
Cite this as: BMJ 2004;328:1221.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Liza Gibson
  1. London

    Doctors' leaders and consumer bodies have raised concerns about the UK government's decision to allow the cholesterol lowering agent, simvastatin, to become available without prescription in pharmacies.

    The reclassification, announced last week by the Department of Health to increase patients' choice and to help reduce coronary heart disease, will be the world's first for a statin. About 1.8 million people in England are prescribed statins, costing the NHS around £700m ($1200m; €1000m) a year. Some £309m is spent on simvastatin alone.

    The over the counter product, to be called Zocor Heart-Pro (10 mg), will be aimed at …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular